Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
American Bar Association, Landslide Webinar Series
Schiff Hardin LLP
9th Annual Pharma IPR Conference 2020
Ninety-nine Schiff Hardin lawyers have been named to the 2017 Leading Lawyers list for Illinois and Michigan.
The Center for Biosimilars
The National Law Journal
Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.
Ninety-six Schiff Hardin lawyers have been named to the 2018 Leading Lawyers lists for Illinois and Michigan.
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Schiff Hardin LLP is pleased to have 95 attorneys named to the 2019 Leading Lawyers list.
Biosimilars Review & Report
Schiff Hardin LLP represented Snap-on Incorporated (NYSE:SNA), a manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions, in its acquisition of Power Hawk Technologies for approximately $8 million.
Schiff Hardin LLP is pleased to announce that 88 attorneys have been named to the 2020 Leading Lawyers list.
Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.
Schiff Hardin won an appeal for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., showing a formulation patent claim is invalid and helping generics further develop the “inherent obviousness” case law.
We are pleased to announce that 32 Schiff Hardin attorneys have been recognized on the 2020 Illinois Super Lawyers and Rising Stars lists.
Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.
The U.S. Food and Drug Administration (FDA) issued a guidance document today outlining its procedures for conducting clinical trials of investigational products in view of the worldwide COVID-19 outbreak.
Lost in the proceedings that have occupied our collective attention these last few months was the passage of the omnibus “Further Consolidated Appropriations Act, 2020,” which became law in late December and kept our country operating (at least for the near term).
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).